Fi3 FINANCIAL ADVISORS LLC Has $223,000 Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Fi3 FINANCIAL ADVISORS LLC lessened its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 660 shares of the medical equipment provider’s stock after selling 41 shares during the quarter. Fi3 FINANCIAL ADVISORS LLC’s holdings in Intuitive Surgical were worth $223,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of ISRG. WCM Investment Management LLC acquired a new stake in shares of Intuitive Surgical during the fourth quarter worth $575,536,000. International Assets Investment Management LLC raised its stake in Intuitive Surgical by 32,360.5% in the 4th quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock worth $231,721,000 after purchasing an additional 684,749 shares in the last quarter. Alphinity Investment Management Pty Ltd boosted its holdings in Intuitive Surgical by 113.2% in the 4th quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock valued at $430,525,000 after purchasing an additional 677,455 shares during the period. J.P. Morgan Private Wealth Advisors LLC acquired a new position in shares of Intuitive Surgical during the 3rd quarter worth approximately $178,667,000. Finally, Quadrature Capital Ltd increased its holdings in shares of Intuitive Surgical by 466.2% during the third quarter. Quadrature Capital Ltd now owns 340,644 shares of the medical equipment provider’s stock worth $99,601,000 after purchasing an additional 280,480 shares during the period. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Up 1.0 %

ISRG traded up $3.71 during trading on Friday, hitting $381.36. The company’s stock had a trading volume of 1,028,858 shares, compared to its average volume of 1,492,254. The firm has a market capitalization of $135.27 billion, a P/E ratio of 68.84, a PEG ratio of 4.88 and a beta of 1.39. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $403.76. The stock’s fifty day moving average price is $385.40 and its 200-day moving average price is $349.30.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. The business had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The firm’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same period in the prior year, the business earned $1.00 EPS. Equities research analysts expect that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on ISRG. Barclays raised their price objective on Intuitive Surgical from $385.00 to $430.00 and gave the stock an “overweight” rating in a research note on Thursday, January 25th. Royal Bank of Canada upped their price target on shares of Intuitive Surgical from $400.00 to $432.00 and gave the stock an “outperform” rating in a report on Wednesday, January 24th. BTIG Research lifted their price objective on shares of Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a research note on Friday, April 19th. Citigroup upped their target price on Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Finally, Jefferies Financial Group lifted their price target on Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research note on Friday, April 19th. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $396.17.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 376 shares of the firm’s stock in a transaction on Monday, April 29th. The stock was sold at an average price of $375.39, for a total transaction of $141,146.64. Following the transaction, the executive vice president now directly owns 5,507 shares in the company, valued at approximately $2,067,272.73. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Intuitive Surgical news, EVP Robert Desantis sold 376 shares of the stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $375.39, for a total value of $141,146.64. Following the completion of the sale, the executive vice president now owns 5,507 shares in the company, valued at approximately $2,067,272.73. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Alan J. Levy sold 2,000 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total transaction of $741,400.00. Following the transaction, the director now directly owns 25,319 shares in the company, valued at approximately $9,385,753.30. The disclosure for this sale can be found here. In the last quarter, insiders sold 226,928 shares of company stock worth $87,833,828. Insiders own 0.90% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.